Cure My Disease

Don't miss your cure!

 Log in / Sign up

Ultrasound maps gluteal muscle to improve depot injection safety

NCT ID NCT07815587

Knowledge-focused Sponsor: St. Olavs Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 11, 2026 · Last updated Sep 11, 2026

Summary

Researchers at St. Olavs Hospital are using ultrasound to measure the gluteal muscle in adults who receive depot antipsychotic injections and in healthy volunteers. The study aims to better understand the anatomy relevant to giving these long-acting injections into the buttocks. By measuring the distance from skin to muscle, the team hopes to identify the best injection site and reduce potential problems.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors choose safer injection sites for depot antipsychotic medications, potentially reducing discomfort or complications.
What could go wrong
This is a small observational study with 60 participants, so findings may not apply to everyone. Ultrasound measurements alone may not capture all factors that affect injection safety.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults receiving depot antipsychotic medication

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * adults receiving depot antipsychotic medication and able to provide informed consent. Healthy volunteers: adults able to provide informed consent. Exclusion Criteria: * Acute infections at the injection site * Previous surgery that makes ultrasound examination difficult

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Intramuscular injection are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psychotic disorder Psychotic Disorders schizophrenia 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Intramuscular injection Psychotic disorder Schizophrenia 1 (disorder)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.